BTIG Reiterates Buy on Abivax, Maintains $175 Price Target
BTIG analyst Julian Harrison reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.
Stocks · News reference
Earnings Scheduled For September 21, 2026
Companies Reporting Before The Bell • Ennis (NYSE:EBF) is expected to report earnings for its second quarter. Companies Reporting After The Bell • Abivax (NASDAQ:ABVX) is projected to report quarterly loss at $1.08 per
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.
Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $155 to $151.
Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.
8-K filing — ENNIS, INC. (EBF)
Filed: 2026-09-21 AccNo: 0001193125-26-396197 Size: 586 KB Item 2.02: Results of Operations and Financial Condition Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Ennis Q2 EPS $0.37 Misses $0.39 Estimate, Sales $102.006M Beat $99.850M Estimate
Ennis (NYSE:EBF) reported quarterly earnings of $0.37 per share which missed the analyst consensus estimate of $0.39 by 5.13 percent. This is a 27.45 percent decrease over earnings of $0.51 per share from the same